107 related articles for article (PubMed ID: 8491067)
1. Subjective and physiologic effects of intravenous buprenorphine in humans.
Pickworth WB; Johnson RE; Holicky BA; Cone EJ
Clin Pharmacol Ther; 1993 May; 53(5):570-6. PubMed ID: 8491067
[TBL] [Abstract][Full Text] [Related]
2. Sublingual versus subcutaneous buprenorphine in opiate abusers.
Jasinski DR; Fudala PJ; Johnson RE
Clin Pharmacol Ther; 1989 May; 45(5):513-9. PubMed ID: 2721107
[TBL] [Abstract][Full Text] [Related]
3. Effects of high-dose intravenous buprenorphine in experienced opioid abusers.
Umbricht A; Huestis MA; Cone EJ; Preston KL
J Clin Psychopharmacol; 2004 Oct; 24(5):479-87. PubMed ID: 15349002
[TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacology of buprenorphine: ceiling effects at high doses.
Walsh SL; Preston KL; Stitzer ML; Cone EJ; Bigelow GE
Clin Pharmacol Ther; 1994 May; 55(5):569-80. PubMed ID: 8181201
[TBL] [Abstract][Full Text] [Related]
5. Intravenous buprenorphine reduces pupil size and the light reflex in humans.
Pickworth WB; Bunker E; Welch P; Cone E
Life Sci; 1991; 49(2):129-38. PubMed ID: 2062170
[TBL] [Abstract][Full Text] [Related]
6. Comparison of intravenous buprenorphine and methadone self-administration by recently detoxified heroin-dependent individuals.
Comer SD; Sullivan MA; Walker EA
J Pharmacol Exp Ther; 2005 Dec; 315(3):1320-30. PubMed ID: 16144974
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacodynamics of multiple sublingual buprenorphine tablets in dose-escalation trials.
Ciraulo DA; Hitzemann RJ; Somoza E; Knapp CM; Rotrosen J; Sarid-Segal O; Ciraulo AM; Greenblatt DJ; Chiang CN
J Clin Pharmacol; 2006 Feb; 46(2):179-92. PubMed ID: 16432270
[TBL] [Abstract][Full Text] [Related]
8. Acute administration of buprenorphine in humans: partial agonist and blockade effects.
Walsh SL; Preston KL; Bigelow GE; Stitzer ML
J Pharmacol Exp Ther; 1995 Jul; 274(1):361-72. PubMed ID: 7542336
[TBL] [Abstract][Full Text] [Related]
9. Acute interactions of buprenorphine with intravenous cocaine and morphine: an investigational new drug phase I safety evaluation.
Teoh SK; Mendelson JH; Mello NK; Kuehnle J; Sintavanarong P; Rhoades EM
J Clin Psychopharmacol; 1993 Apr; 13(2):87-99. PubMed ID: 8463453
[TBL] [Abstract][Full Text] [Related]
10. Respiratory and cardiovascular effects of buprenorphine in conscious rabbits.
Shafford HL; Schadt JC
Vet Anaesth Analg; 2008 Jul; 35(4):326-32. PubMed ID: 18282250
[TBL] [Abstract][Full Text] [Related]
11. Buprenorphine and naloxone alone and in combination in opioid-dependent humans.
Preston KL; Bigelow GE; Liebson IA
Psychopharmacology (Berl); 1988; 94(4):484-90. PubMed ID: 2453895
[TBL] [Abstract][Full Text] [Related]
12. The respiratory depressive effects of intravenous buprenorphine in patients in an intensive care unit.
Downing JW; Goodwin NM; Hicks J
S Afr Med J; 1979 Jun; 55(25):1023-7. PubMed ID: 483080
[TBL] [Abstract][Full Text] [Related]
13. Subjective, behavioral, and physiologic responses to intravenous dezocine in healthy volunteers.
Zacny JP; Lichtor JL; de Wit H
Anesth Analg; 1992 Apr; 74(4):523-30. PubMed ID: 1348168
[TBL] [Abstract][Full Text] [Related]
14. Buprenorphine reduces cerebral glucose metabolism in polydrug abusers.
Walsh SL; Gilson SF; Jasinski DR; Stapleton JM; Phillips RL; Dannals RF; Schmidt J; Preston KL; Grayson R; Bigelow GE
Neuropsychopharmacology; 1994 May; 10(3):157-70. PubMed ID: 7916913
[TBL] [Abstract][Full Text] [Related]
15. Buprenorphine effects in methadone-maintained volunteers: effects at two hours after methadone.
Strain EC; Preston KL; Liebson IA; Bigelow GE
J Pharmacol Exp Ther; 1995 Feb; 272(2):628-38. PubMed ID: 7853176
[TBL] [Abstract][Full Text] [Related]
16. Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans.
Bickel WK; Stitzer ML; Bigelow GE; Liebson IA; Jasinski DR; Johnson RE
J Pharmacol Exp Ther; 1988 Oct; 247(1):47-53. PubMed ID: 2459370
[TBL] [Abstract][Full Text] [Related]
17. Comparing the subjective, psychomotor and physiological effects of intravenous buprenorphine and morphine in healthy volunteers.
Zacny JP; Conley K; Galinkin J
J Pharmacol Exp Ther; 1997 Sep; 282(3):1187-97. PubMed ID: 9316825
[TBL] [Abstract][Full Text] [Related]
18. Intravenous buprenorphine self-administration by detoxified heroin abusers.
Comer SD; Collins ED; Fischman MW
J Pharmacol Exp Ther; 2002 Apr; 301(1):266-76. PubMed ID: 11907183
[TBL] [Abstract][Full Text] [Related]
19. Opioid partial agonist buprenorphine dampens responses to psychosocial stress in humans.
Bershad AK; Jaffe JH; Childs E; de Wit H
Psychoneuroendocrinology; 2015 Feb; 52():281-8. PubMed ID: 25544740
[TBL] [Abstract][Full Text] [Related]
20. The effects of buprenorphine in buprenorphine-maintained volunteers.
Strain EC; Walsh SL; Preston KL; Liebson IA; Bigelow GE
Psychopharmacology (Berl); 1997 Feb; 129(4):329-38. PubMed ID: 9085402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
